You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

 

Online download statistics by month:

Online download statistics by month: September 2023 to July 2025

AbstractFullPdf
Sep 2023482482143
Oct 2023353355119
Nov 202320220289
Dec 202318718889
Jan 2024177178117
Feb 202451351363
Mar 2024251252101
Apr 2024140141100
May 202411911991
Jun 202415915980
Jul 202414915181
Aug 202410710557
Sep 2024103104185
Oct 2024104109193
Nov 202412612792
Dec 202414314689
Jan 2025929271
Feb 2025191191117
Mar 202512012088
Apr 2025191192104
May 202510410562
Jun 2025616136
Jul 2025110
Total407540932167